Structure Therapeutics Inc. 4

Chief Scientific Officer Xichen Lin exercised options into Ordinary Shares of Structure Therapeutics Inc. (GPCR), converted them into 7,878 ADSs, and sold all 7,878 ADSs in open-market trades totaling roughly $402K on July 14, 2026.

On July 14, 2026, Chief Scientific Officer Xichen Lin of Structure Therapeutics Inc. exercised an employee stock option for 23,634 Ordinary Shares at an exercise price of $0.34 per Ordinary Share (aggregate cost of roughly $8,000), immediately converted those Ordinary Shares into 7,878 American Depositary Shares (ADSs), and then sold a total of 7,878 ADSs in two open-market transactions under a pre-established Rule 10b5-1 trading plan at weighted average prices of $50.7956 (6,278 ADSs) and $51.7088 (1,600 ADSs), for total gross sale proceeds of approximately $402,000. Following the partial option exercise, 166,532 Ordinary Shares remain subject to the option, 252,594 Ordinary Shares and 4,800 ADSs are reported as directly owned, implying a post-transaction holding value on the order of $1.0–1.1 million at the prevailing ADS price, while 228,960 Ordinary Shares appear to be reported as indirectly or differently categorized holdings, all reflecting a combination of routine equity compensation activity and liquidity sales rather than a net open-market purchase.

Filing Facts

CIK

1888886

Ticker

GPCR

Form

4

Source Type

fda

Accession

0001962926-26-000006

Alert Tier

6